Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

We want you to take advantage of everything Clinical Advisor has to offer. To view unlimited content, log in or register for free.

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

A decision is expected in the fourth quarter of 2025.

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

The prospect of a pill rather than an injection is obviously appealing to some people, but will fear of needles be enough to ...

The SOUL trial showed that oral semaglutide was safe in patients with type 2 diabetes and atherosclerotic cardiovascular ...

Despite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final ...

The risk for ocular problems linked to different formulations of semaglutide appear to vary, according to a new study, which ...

Compared with other antidiabetic medications, semaglutide was linked to a significantly lower risk of opioid overdose in ...